Compare MYO & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | DYAI |
|---|---|---|
| Founded | 2004 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 30.8M |
| IPO Year | 2017 | 2003 |
| Metric | MYO | DYAI |
|---|---|---|
| Price | $0.69 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $7.67 | $3.00 |
| AVG Volume (30 Days) | ★ 412.0K | 66.4K |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000,000.00 | $3,495,389.00 |
| Revenue This Year | $15.92 | $12.52 |
| Revenue Next Year | $21.49 | $92.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40814.79 | 20.58 |
| 52 Week Low | $0.64 | $0.71 |
| 52 Week High | $5.62 | $1.55 |
| Indicator | MYO | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 39.44 | 40.36 |
| Support Level | $0.68 | $0.73 |
| Resistance Level | $1.03 | $1.01 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 25.21 | 14.76 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.